Previous close | 10.00 |
Open | 10.00 |
Bid | 4.10 |
Ask | 18.20 |
Strike | 250.00 |
Expiry date | 2026-12-18 |
Day's range | 10.00 - 10.00 |
Contract range | N/A |
Volume | |
Open interest | 10 |
On May 22, 2024, Bruce Sachs, Director at Vertex Pharmaceuticals Inc (NASDAQ:VRTX), executed a sale of 7,073 shares of the company.
Cystic fibrosis treatment leader Vertex scored a breakout from a cup base this week, just a few weeks after an earnings beat.
On May 20, 2024, Reshma Kewalramani, CEO & President of Vertex Pharmaceuticals Inc (NASDAQ:VRTX), executed a sale of 15,202 shares of the company, according to the SEC Filing.